ubrogepant

CHEBI:CHEBI_751871

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2268231
generic_name
Ubrogepant
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
labeler_name
Ubrogepant
manufacturer_name
Allergan, Inc.
listing_expiration_date
20241231
route
ORAL
dosage_form
POWDER
active_ingredient_strength
50 kg/50kg
marketing_start_date
20230822
package_marketing_start_date
22-AUG-23
nui
N0000193918
pharm_class_epc
Calcitonin Gene-related Peptide Receptor Antagonist [EPC]
pharm_class
Calcitonin Gene-related Peptide Receptor Antagonists [MoA]
pharm_class_moa
Calcitonin Gene-related Peptide Receptor Antagonists [MoA]
brand_name
UBRELVY
brand_name_base
UBRELVY
product_ndc
0023-6499
application_number
NDA211765
spl_id
f489f5a5-6a3a-402f-8796-71ec6fb24b47
active_ingredient_name
UBROGEPANT
package_ndc
0023-6499-00
package_description
1 BAG in 1 DRUM (0023-6499-00) / 13200 TABLET in 1 BAG
unii
AD0O8X2QJR
spl_set_id
fd9f9458-fd96-4688-be3f-f77b3d1af6ab
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class